The COVID-19 pandemic triggered an unprecedented surge in clinical research, leading to thousands of studies aimed at understanding, managing, and ultimately controlling the virus. As healthcare systems worldwide faced the immense challenge of treating patients, researchers raced against time to … Read More
Author Archives: admin
SOURCE Trial: Sorafenib in Portal Vein Tumor Thrombus
Here’s the extracted information from the provided visual abstract: SOURCE Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcomes: Conclusion: Citation: This summary captures the key points from the … Read More
SABATO Trial: Oral Antibiotics for Staph Aureus
Here’s the extracted information from the provided visual abstract: SABATO Efficacy and Safety of an Early Oral Switch in Low-risk Staphylococcus aureus Bloodstream Infection Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcome: Conclusion: Citation: This summary captures the … Read More
OPT-BIRISK Trial: Clopidogrel Monotherapy in High Risk ACS
Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
CheckMate 77T Trial: Nivolumab in Lung Cancer
CheckMate 77TPerioperative Nivolumab in Resectable Lung Cancer Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with … Read More
SEQUOIA-HCM Trial: Aficamten in HCM
SEQUOIA-HCMAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the SEQUOIA-HCM trial, comparing the outcomes of aficamten versus placebo in patients with … Read More
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
NOTUS Trial: Dupilumab in COPD
NOTUS TRIAL Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation A double-blind, placebo-controlled, randomized trial Objective:To assess the efficacy and safety of dupilumab in patients with moderate to severe COPD and evidence of type 2 inflammation. 935 … Read More
IRONMAN Trial: IV Iron in HF
IRONMAN Trial Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency A randomized, open-label, blinded-endpoint trial Objective:To evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure … Read More
INTERACT4 Trial: Ambulance care for Stroke
INTERACT4 Trial Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke A multicentre, randomized, open-label trial Objective:To determine the effect of prehospital treatment of elevated systolic blood pressure (SBP) in patients with recent onset of symptoms concerning for acute stroke. 2404 Patients … Read More